PDF herunterladen
Dtsch Med Wochenschr 2014; 139(49): 2517-2519
DOI: 10.1055/s-0034-1387451
Kardiologie | Commentary
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Herzinsuffizienz: Neue Erkenntnisse und Entwicklungen

Heart failure: new insights and developments
M. Hundertmark
1   Universitätsklinik und Poliklinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Halle (Saale)
,
S. Frantz
1   Universitätsklinik und Poliklinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Halle (Saale)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. November 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Schlüsselwörter

Herzinsuffizienz - HFpEF - HFrEF - CRT

Keywords

heart failure - HFpEF - HFrEF - CRT
 

  • Literatur

  • 1 Conraads VM et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012; 14: 219-225
    CrossrefPubMedGoogle Scholar
  • 2 Dschietzig TB. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?. Am J Carciovasc Drugs 2014; 14: 343-355
    PubMedGoogle Scholar
  • 3 Edelmann F et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791
    Google Scholar
  • 4 Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circ Heart Fail 2009; 2: 56-62
    CrossrefPubMedGoogle Scholar
  • 5 Levy D et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402
    CrossrefPubMedGoogle Scholar
  • 6 McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004
    CrossrefPubMedGoogle Scholar
  • 7 Moss AJ et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-1338
    CrossrefPubMedGoogle Scholar
  • 8 Owan TE et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259
    CrossrefPubMedGoogle Scholar
  • 9 Pitt B et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392
    CrossrefPubMedGoogle Scholar
  • 10 Pitt B et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
    Google Scholar
  • 11 Roger VL et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344-350
    CrossrefPubMedGoogle Scholar
  • 12 Ruschitzka F et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369: 1395-1405
    CrossrefPubMedGoogle Scholar
  • 13 Volpe M. Natriuretic peptides and cardio-renal disease. Intern J Cardiol 2014; 176: 630-639
    CrossrefPubMedGoogle Scholar
  • 14 von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Therap 2014; 144: 41-49
    CrossrefPubMedGoogle Scholar
  • 15 Yusuf S et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781
    CrossrefPubMedGoogle Scholar
  • 16 Teerlink JR et al. Seralaxin, recombinant human relaxin-2, for treatment of acute heart failure (relax-ahf): A randomised, placebo-controlled trial. Lancet 2013; 381: 29-39
    CrossrefPubMedGoogle Scholar